Drug intelligence / Profile preview

Td vaccine (GCBC Vaccines)

Development stage: Approved
Lead developer: GCBC Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Td vaccine (GCBC Vaccines) is a combination vaccine candidate currently in development by GCBC Vaccines for the prevention of tetanus and diphtheria. The vaccine is intended to induce active immunity against the toxins produced by *Clostridium tetani* and *Corynebacterium diphtheriae*. As a pipeline product for GCBC Vaccines, it aims to expand the company's portfolio of bacterial vaccines, which currently includes the approved oral cholera vaccine, Shanchol. The specific formulation details, such as the use of adjuvants or the exact concentration of toxoids, have not been publicly disclosed in the provided pipeline information.

Other names: tetanus and diphtheria vaccineTd vaccineTetanus-Diphtheria vaccine

Targets

TT (Tetanus toxoid)

Beyond the preview

Go deeper on Td vaccine (GCBC Vaccines).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Td vaccine (GCBC Vaccines).

Explore the full profile